Get the latest news, insights, and market updates on CAI (Caris Life Sciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Assessing Caris Life Sciences (CAI) Valuation After Recent Share Price Weakness
Caris Life Sciences (CAI) has drawn fresh attention after recent trading left the stock with a one-month return of about a 13% decline and a three-month return near a 23% decline. See our latest analysis for Caris Life Sciences. Those recent share price returns, including a 4.68% 1 day gain and 3.12% 7 day gain against deeper 30 day and year to date share price declines, suggest short term momentum is improving after a weaker stretch. If you are watching how AI driven health companies are... Mar 1, 2026 - $CAI
Caris Life Sciences Q4 Earnings Call Highlights
Caris Life Sciences (NASDAQ:CAI) reported a record fourth quarter in its first full year as a public company, driven by strong growth in its molecular profiling business and improved profitability. Management also outlined plans to reinvest in commercial expansion and product development in 2026, wh Feb 27, 2026 - $CAI
Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report
Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the Best All-Time Low Stocks to Invest In Now. On February 24, Caris Life Sciences, Inc. (NASDAQ:CAI) announced that it is adding a new AI-powered “breast cancer signature” to its Caris Molecular Tumor Board Report. The report is a research tool that doctors and researchers use for […] Feb 27, 2026 - $CAI
/C O R R E C T I O N -- Caris Life Sciences/
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced an interim readout of Achieve 1, the Company's study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test. This interim readout of Achieve 1 represents a major milestone in Caris' goal to detect cancer earlier, when it is most treatable, through Whole Genome Sequencing, advanced AI and molecular insights. Feb 26, 2026 - $CAI
Is Caris Life Sciences (CAI) Pricing Look Attractive After Recent Share Price Pullback
If you are wondering whether Caris Life Sciences at around US$18.31 is starting to look interesting on price, the key question is how its current market value stacks up against its fundamentals. The stock has recently been under pressure, with returns of a 12.2% decline over 7 days, a 29.6% decline over 30 days and a 32.1% decline year to date, which may have shifted how some investors think about its risk and potential reward. Recent news coverage around Caris Life Sciences has focused on... Feb 26, 2026 - $CAI
Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating
Caris Life Sciences, Inc. (NASDAQ:CAI) is among the 11 Newly-Listed NASDAQ Stocks to Buy Now. On February 17, 2026, Baird initiated coverage of Caris Life Sciences, Inc. (NASDAQ:CAI) with an Outperform rating and a $26 price target. Baird described Caris Life Sciences, Inc. (NASDAQ:CAI) as a commercial-stage precision oncology company focused on comprehensive molecular information […] Feb 25, 2026 - $CAI
Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. The Caris Molecular Tumor Board Report is an innovative research-use-only (RUO) tumor profiling report that provides an additional tumor biology resource and is available upon request when ordering MI Cancer Seek®. Feb 24, 2026 - $CAI
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple